Cytocore (OTCMKTS:MDIT) and Cryolife (NYSE:CRY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Insider and Institutional Ownership
71.1% of Cryolife shares are held by institutional investors. 85.4% of Cytocore shares are held by company insiders. Comparatively, 4.0% of Cryolife shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
Cytocore has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Cryolife has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
This table compares Cytocore and Cryolife’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares Cytocore and Cryolife’s revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Cryolife has higher revenue and earnings than Cytocore.
This is a breakdown of recent ratings and price targets for Cytocore and Cryolife, as provided by MarketBeat.com.
||Strong Buy Ratings
Cryolife has a consensus target price of $34.00, indicating a potential upside of 19.55%. Given Cryolife’s higher probable upside, analysts plainly believe Cryolife is more favorable than Cytocore.
Cryolife beats Cytocore on 9 of the 11 factors compared between the two stocks.
Cytocore Company Profile
MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.
Cryolife Company Profile
CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft systems for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G is a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Receive News & Ratings for Cytocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytocore and related companies with MarketBeat.com's FREE daily email newsletter.